Effectiveness of a mRNA Vaccine Booster Dose Against COVID-19 Among Oregon Healthcare Personnel, January 2021-June 2023
Antimicrobial Stewardship & Healthcare Epidemiology · 2025-07 · 5 (S2) · s80-s81
DOI: 10.1017/ash.2025.300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Stewardship & Healthcare Epidemiology, online erschienen am 24.09.2025. Verfasst von Madysen Schreiber und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The prioritization of U.S. health care personnel (HCP) for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) allowed for the evaluation of the effectiveness of these vaccines in a real-world setting among a high-risk population. The purpose of this study was to summarize the sociodemographic characteristics of HCP in Oregon eligible to receive COVID-19 vaccination and estimate vaccine effectiveness (VE) of a mRNA COVID-19 vaccine booster dose.
Methods
We conducted a case-control study involving HCP from 5 hospitals in Oregon. Cases were defined as those with a positive antigen test or nucleic acid amplification test (NAAT) for SARS-CoV-2. Controls were defined as those with a negative antigen test or NAAT result and were matched to cases by site and within a 2-week interval of test date. Using conditional logistic regression with adjustment for age, sex, race and ethnicity, educational level, underlying conditions, and reported exposure to COVID-19, we estimated VE for a 3rd COVID-19 vaccine booster dose (with the 3rd dose more than 150 days after the 2nd dose). VE was estimated using the screening method as 1-odds ratio x 100%.
Results
Among 865 HCP, 374 (43%) were included as case-participants and 491 (57%) as control-participants. Overall, the adjusted VE of a booster dose was 62.6% (95% CI: 37.6%, 77.6%), compared to vaccination with 2 mRNA doses. Logistic regression analysis indicated that HCP with a college degree (vs. no degree, OR: 3.26, 95% CI: 1.96, 5.45), private insurance (vs. government/military, OR: 3.32, 95% CI: 1.28, 8.59), and an income level $200K+ (vs.
Zitieren
APA
Schreiber, M., Hall, E., Ocampo, V., Zhang, A., & Dusko, A. (2025). Effectiveness of a mRNA Vaccine Booster Dose Against COVID-19 Among Oregon Healthcare Personnel, January 2021-June 2023. Antimicrobial Stewardship & Healthcare Epidemiology, 5(S2), s80-s81. https://doi.org/10.1017/ash.2025.300
Vancouver
Schreiber M, Hall E, Ocampo V, Zhang A, Dusko A. Effectiveness of a mRNA Vaccine Booster Dose Against COVID-19 Among Oregon Healthcare Personnel, January 2021-June 2023. Antimicrobial Stewardship & Healthcare Epidemiology. 2025;5(S2):s80-s81. doi:10.1017/ash.2025.300
BibTeX
@article{Schreiber2025,
author = {Schreiber, Madysen and Hall, Eric and Ocampo, Valerie and Zhang, Alexia and Dusko, Angela},
title = {Effectiveness of a mRNA Vaccine Booster Dose Against COVID-19 Among Oregon Healthcare Personnel, January 2021-June 2023},
journal = {Antimicrobial Stewardship & Healthcare Epidemiology},
year = {2025},
volume = {5},
number = {S2},
pages = {s80--s81},
doi = {10.1017/ash.2025.300}
}
EUVIMED